SCHEMBL4798726

SCHEMBL4798726

Cc1cc(C)c2[nH]ccc2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.40
CYP2A6 P11509 3/20 0.40
MAPT P10636 1/20 0.39
BRD4 O60885 1/20 0.38
TAF1 P21675 1/20 0.38
BRPF1 P55201 1/20 0.38
CREBBP Q92793 1/20 0.38
CECR2 Q9BXF3 1/20 0.38
BRD9 Q9H8M2 1/20 0.38
KMT2A Q03164 1/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38
GRIN1 Q05586 1/20 0.38
GRIN2A Q12879 1/20 0.38
GRIN2B Q13224 1/20 0.38
GRIN2C Q14957 1/20 0.38
GRIN3A Q8TCU5 1/20 0.38
HSD17B10 Q99714 1/20 0.38
IKBKB O14920 3/20 0.35
CHUK O15111 3/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tert-Butyl Formate SCHEMBL27584172 0.82 TDP1 (0.39) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL4484912 0.80 AHR (0.47) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL2983533 0.78 ALDH1A1 (0.38) CYP2A6BRD4TAF1BRPF1CREBBP
SCHEMBL1394068 0.78 TNF (0.42) CYP1A2CYP2A6BRD4TAF1BRPF1
SCHEMBL1997793 0.78 ALOX15 (0.45) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL5176001 0.78 XDH (0.40) CYP1A2CYP2A6MAPTBRD4TAF1
SCHEMBL15934119 0.78 TDP1 (0.38) CYP1A2CYP2A6MAPTBRD4TAF1
SCHEMBL2599709 0.78 AHR (0.45) BRD4TAF1BRPF1CREBBPCECR2
SCHEMBL22253018 0.78 SELL (0.41) MAPTBRD4TAF1BRPF1CREBBP
SCHEMBL860074 0.78 AHR (0.50) CYP2A6BRD4TAF1BRPF1CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025068951-A1 COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2025-04-03 WO claimed
EP-4504699-A1 COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF Novartis AG (CH) 2025-02-12 EP claimed
CN-119137099-A Complement factor B inhibitors and uses thereof 诺华股份有限公司 2024-12-13 CN claimed
CN-118001879-A Application of nano copper alloy in filtering harmful substances in cigarette smoke 广东合一新材料研究院有限公司 2024-05-10 CN claimed
WO-2023187715-A1 COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2023-10-05 WO claimed
US-20250243186-A1 PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF HANSOH BIO LLC. 2025-07-31 US disclosed
WO-2025068951-A1 COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2025-04-03 WO disclosed
EP-4504699-A1 COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF Novartis AG (CH) 2025-02-12 EP disclosed
CN-119137099-A Complement factor B inhibitors and uses thereof 诺华股份有限公司 2024-12-13 CN disclosed
CN-118001879-A Application of nano copper alloy in filtering harmful substances in cigarette smoke 广东合一新材料研究院有限公司 2024-05-10 CN disclosed
US-11827602-B2 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors Janssen Pharmaceuticals, Inc. (US) 2023-11-28 US disclosed
WO-2023187715-A1 COMPLEMENT FACTOR B INHIBITORS AND USES THEREOF NOVARTIS AG (CH) 2023-10-05 WO disclosed
US-20060160876-A1 (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic SALMEDIX, INC. 2006-07-20 US disclosed
EP-1680428-A2 SUBSTITUTED INDOLE DERIVATIVES CEPHALON, INC. (US) 2006-07-19 EP disclosed
EP-1673373-A2 INDOLE DERIVATIVES Salmedix, Inc. (US) 2006-06-28 EP disclosed
WO-2005033112-A2 SUBSTITUTED INDOLE DERIVATIVES CEPHALON, INC. (US) 2005-04-14 WO disclosed
WO-2005033113-A2 INDOLE DERIVATIVES CEPHALON, INC (US) 2005-04-14 WO disclosed
WO-1995034658-A1 MICROBIAL PRODUCTION OF INDOLE-3-ACETIC ACIDS AND SUBSTITUTED ANALOGS THEREOF VIA FERMENTATION GENENCOR INTERNATIONAL, INC. (US) 1995-12-21 WO disclosed
WO-1995034657-A2 MICROBIAL PRODUCTION OF 4-, 5-, 6- AND 7-SUBSTITUTED INDOLE AND TRYPTOPHAN ANALOGS VIA FERMENTATION GENENCOR INTERNATIONAL, INC. (US) 1995-12-21 WO disclosed
US-4731353-A METAL SALT OF INDOLE-2-CARBOXYLIC ACID COLOR DEVELOPER KANZAKI PAPER MANUFACTURING COMPANY, LIMITED (JP) 1988-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160876-A1 (6-Bromo-1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid ethyl ester; antineoplastic, anti-inflammatory, analgesic IL6, OPRK1, PTGES3 CYP1A2 391/4885CYP2A6 141/4885MAPT 2112/4885
US-11827602-B2 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors IDO1, IDO2, IRF3 CYP1A2 1410/4885CYP2A6 1720/4885MAPT 2371/4885
US-20250243186-A1 PIPERIDINYL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICINAL USES THEREOF IDO1, IDO2, TPH1 CYP1A2 145/4885CYP2A6 737/4885MAPT 1750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.